Stem Cell Network Welcomes Four New Board Members and Announces New Board Chair and Vice Chair

(Ottawa – November 26, 2025) — The Stem Cell Network (SCN) is pleased to announce the appointment of four new expert members to its Board of Directors. SCN is also delighted to share that Tamer Mohamed, Founder & CEO of Aspect Biosystems, has assumed the role of Chair, and Nadine Beauger, Senior Director of Technology and Innovation Development Office, at Boston Children’s Hospital has taken on the position of Vice Chair. SCN’s outgoing Board Chair, Declan Hamill, will continue to serve on the Board for an additional year.

SCN’s Board of Directors is comprised of volunteer members from across Canada who serve as champions for the organization, provide strategic guidance, and support SCN’s management in fulfilling its fiduciary responsibilities.  Directors are appointed for three-year terms and may be reappointed for a second term.

Tamer Mohamed, a bioengineer, inventor, and entrepreneur, serves as CEO of Aspect Biosystems. Tamer co-founded Aspect and has since played a leading role in overall corporate, business, and technology development. Under his leadership, Aspect has secured significant funding, entered strategic collaborations with best-in-class pharmaceutical and biotechnology companies, and built a world-class team. Read more.

Nadine Beauger is Senior Director of the Therapeutic Accelerator at the Boston Children’s Hospital, Technology & Innovation Development Office (TIDO). She plays an integral role in driving hospital innovations to advance TIDO’s mission of improving the health and well-being of children around the world. Dr. Beauger is a Senior Executive with more than 25 years of proven expertise in building and delivering high value drug discovery assets in life sciences including corporate and business strategy, technology identification and transfer, project management, venture capital, intellectual property, and drug discovery research. Read more.

John Alho is one the longest serving government relations professionals in the Canadian post-secondary sector, currently serving as the Associate Vice-President, Government Relations, at the University of Calgary. John works closely with the President and other members of the University’s leadership team, to further the University of Calgary’s external relations objectives. He has significant expertise in advocacy, public relations, public policy formulation, strategic communications, marketing, and community engagement. Read more.

Wayne Critchley is Senior Associate with Global Public Affairs’ Health & Life Sciences practice, providing counsel to leading biopharmaceutical and medical device corporations and associations along with other health policy stakeholders. Wayne has a long track record of success as a senior executive with over twenty years of experience in government departments, boards and agencies dealing primarily with issues that impact the pharmaceutical sector. Read more.

Susan Marlin is a trusted leader in Canada’s research ethics and clinical trials community. As the President and CEO of Clinical Trials Ontario (CTO), she collaborates to strengthen the clinical trials environment while maintaining the highest ethical and quality standards. Susan was foundational in establishing CTO’s streamlined research ethics review system to enable a single review for multi-site clinical trials and health research studies in Ontario which now has more than 11,000 users, 160 participating sites, 300 pharmaceutical and medical device companies, and 20 qualified research ethics boards. Read more.

Liz Williams has nearly 20 years of experience in biotech, working with publicly listed entities in both Canada and the United States. She is currently the CFO at Satellos Bioscience Inc. (TSX: MSCL) where she is responsible for all financial, legal, and investor relations functions. Prior to joining Satellos, Ms. Williams was CFO of Medicenna (Nasdaq: MDNA) where she led a listing on the Nasdaq. Previous to Medicenna, she was Vice President of Finance and Administration at Aptose Biosciences Inc. (Nasdaq: APTO). Read more.

Quotes:
“I am delighted to welcome our new Board members and extend my sincere thanks to Tamer and Nadine for taking on key leadership roles with SCN. Collectively, their breadth of knowledge and expertise will be invaluable as we work to implement the four pillars of our strategic plan, Accelerate. I look forward to working with all of them in the years ahead. I would also like to extend my heartfelt thanks to Declan Hamill for his steady leadership and thoughtful guidance as Chair. His commitment to strong governance and his support for the SCN team has been truly appreciated.”
— Cate Murray, President and CEO, Stem Cell Network

“I am honoured to step into the role of Chair and to continue supporting SCN’s mission to transform lives through regenerative medicine. I look forward to working closely with my fellow Board members and the dedicated SCN team as we build on the strong foundation already in place. Canada has a proud and pioneering history in regenerative medicine, and I am excited to chair a Board that is deeply committed to advancing impactful research in this field.”
— Tamer Mohamed, Chair of the Board of Directors, Stem Cell Network & CEO of Aspect Biosystems